Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis

Myocarditis is the most salient serious adverse event following messenger RNA-based Covid-19 vaccines. The highest risk is observed after the second dose compared to the first, whereas the level of risk associated with more distant booster doses seems to lie in between. We aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster). This matched case-control study included 7911 cases of myocarditis aged 12 or more in a period where approximately 130 million vaccine doses were administered. Here we show that longer intervals between each consecutive dose, including booster, may decrease the occurrence of vaccine-associated myocarditis by up to a factor of 4, especially under age 50. These results suggest that a minimum 6-month interval might be required when scheduling additional booster vaccination.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2024-09-05
DOI
https://doi.org/10.1038/s41467-024-52038-6
Citations
12
Primary Topic
Viral Infections and Immunology Research
Type
article
Field-Weighted Citation Impact
4.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis

Marie-Joëlle Jabagi, Jérôme Drouin, Stéphane Le Vu, Marion Bertrand et al.
12 citations
Nature Communications
Viral Infections and Immunology Research
4.82
article

Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis

Marie-Joëlle Jabagi, Jérôme Drouin, Stéphane Le Vu, Marion Bertrand, Rosemary Dray‐Spira, Laura Semenzato, Mahmoud Zureik, Jérémie Botton, Alain Weill
article en
12 citations

Abstract

Myocarditis is the most salient serious adverse event following messenger RNA-based Covid-19 vaccines. The highest risk is observed after the second dose compared to the first, whereas the level of risk associated with more distant booster doses seems to lie in between. We aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster). This matched case-control study included 7911 cases of myocarditis aged 12 or more in a period where approximately 130 million vaccine doses were administered. Here we show that longer intervals between each consecutive dose, including booster, may decrease the occurrence of vaccine-associated myocarditis by up to a factor of 4, especially under age 50. These results suggest that a minimum 6-month interval might be required when scheduling additional booster vaccination.

Nature CommunicationsVol. 15(1)
Conservatoire National des Arts et Métiers (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris-Saclay (FR), Centre de recherche en Epidémiologie et Santé des Populations (FR), Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Zero hunger
Openalex Percentile: Top 4%
Viral Infections and Immunology Research
4.82
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.